This poster, presented in December 2015 at the 38th San Antonio Breast Cancer Symposium meeting in San Antonio, Texas, highlights areas of consensus and disagreement among breast cancer experts and clinicians who used an innovative online treatment decision tool for neoadjuvant or adjuvant treatment of EBC.
Community physicians do not consistently align with expert recommendations for use of neoadjuvant or adjuvant therapy for many patients with EBC. For example, whereas experts did not recommend hormonal neoadjuvant therapy, 71% of tool users would use hormonal neoadjuvant therapy for HR+ EBC. Furthermore, not all tool users selected dual HER2-targeted neoadjuvant therapy even though all experts recommended this treatment for HER2+ EBC.
These data suggest that online tools providing customized, patient-specific expert advice may aid clinicians in optimizing treatment decisions for their patients with EBC.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.